These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20853141)

  • 21. Pathogenesis of Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis.
    Yuki N
    Jpn J Infect Dis; 1999 Jun; 52(3):99-105. PubMed ID: 10507987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis.
    Koga M; Gilbert M; Takahashi M; Li J; Koike S; Hirata K; Yuki N
    J Infect Dis; 2006 Feb; 193(4):547-55. PubMed ID: 16425134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review.
    Poropatich KO; Walker CL; Black RE
    J Health Popul Nutr; 2010 Dec; 28(6):545-52. PubMed ID: 21261199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of preceding Campylobacter jejuni infection by polymerase chain reaction in patients with Guillain-Barré syndrome.
    Sinha S; Prasad KN; Pradhan S; Jain D; Jha S
    Trans R Soc Trop Med Hyg; 2004 Jun; 98(6):342-6. PubMed ID: 15099989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni.
    McCarthy N; Giesecke J
    Am J Epidemiol; 2001 Mar; 153(6):610-4. PubMed ID: 11257070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exchange of lipooligosaccharide synthesis genes creates potential Guillain-Barre syndrome-inducible strains of Campylobacter jejuni.
    Phongsisay V; Perera VN; Fry BN
    Infect Immun; 2006 Feb; 74(2):1368-72. PubMed ID: 16428786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh.
    Islam Z; Jacobs BC; van Belkum A; Mohammad QD; Islam MB; Herbrink P; Diorditsa S; Luby SP; Talukder KA; Endtz HP
    Neurology; 2010 Feb; 74(7):581-7. PubMed ID: 20157160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphocyte transformation test detects a response to Campylobacter jejuni antigens in patients with Guillain-Barré syndrome.
    Nyati KK; Prasad KN; Rizwan A; Verma A; Paliwal VK; Pradhan S
    Med Microbiol Immunol; 2010 May; 199(2):109-16. PubMed ID: 20157729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guillain-Barré syndrome associated with Campylobacter jejuni infection in England, 2000-2001.
    Tam CC; Rodrigues LC; O'Brien SJ
    Clin Infect Dis; 2003 Jul; 37(2):307-10. PubMed ID: 12856224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved serological diagnosis stresses the major role of Campylobacter jejuni in triggering Guillain-Barré syndrome.
    Schmidt-Ott R; Schmidt H; Feldmann S; Brass F; Krone B; Gross U
    Clin Vaccine Immunol; 2006 Jul; 13(7):779-83. PubMed ID: 16829615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative genomic analysis of Campylobacter jejuni associated with Guillain-Barré and Miller Fisher syndromes: neuropathogenic and enteritis-associated isolates can share high levels of genomic similarity.
    Taboada EN; van Belkum A; Yuki N; Acedillo RR; Godschalk PC; Koga M; Endtz HP; Gilbert M; Nash JH
    BMC Genomics; 2007 Oct; 8():359. PubMed ID: 17919333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The iron-binding protein Dps confers hydrogen peroxide stress resistance to Campylobacter jejuni.
    Ishikawa T; Mizunoe Y; Kawabata S; Takade A; Harada M; Wai SN; Yoshida S
    J Bacteriol; 2003 Feb; 185(3):1010-7. PubMed ID: 12533477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Preliminary analysis on the proteomic feature of Guillain-Barré syndrome-associated Campylobacter jejuni].
    Tian XY; Zhang JZ; Li CY; He LH; Liu RC; Yin Y; Zou QH; Zhao Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Mar; 25(3):240-4. PubMed ID: 15200939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensory Guillain-Barré syndrome after Campylobacter jejuni infection.
    Rajabally YA; Kass-Hout T; Wilson P; Damian MS
    Eur J Neurol; 2007 Mar; 14(3):e11-2. PubMed ID: 17355531
    [No Abstract]   [Full Text] [Related]  

  • 35. A descriptive study of Guillain-Barré syndrome in high and low Campylobacter jejuni incidence regions of Michigan: 1992-1999.
    Church Potter R; Kaneene JB
    Neuroepidemiology; 2003; 22(4):245-8. PubMed ID: 12792145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Guillain-Barre syndrome and Campylobacter].
    Engberg JH
    Ugeskr Laeger; 2002 Dec; 164(50):5905-8. PubMed ID: 12553106
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationship between pathogenesis of Guillain-Barre syndrome and Penner's serotypes of Campylobacter jejuni.
    Li H; Yuan J; Shen B; Sun X; Hao H
    Chin Med J (Engl); 1999 Sep; 112(9):794-6. PubMed ID: 11717947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship of Campylobacter jejuni infection and the development of Guillain-Barré syndrome.
    Tsang RS
    Curr Opin Infect Dis; 2002 Jun; 15(3):221-8. PubMed ID: 12015454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes.
    Godschalk PC; Kuijf ML; Li J; St Michael F; Ang CW; Jacobs BC; Karwaski MF; Brochu D; Moterassed A; Endtz HP; van Belkum A; Gilbert M
    Infect Immun; 2007 Mar; 75(3):1245-54. PubMed ID: 17261613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Campylobacter DNA is present in circulating myelomonocytic cells of healthy persons and in persons with Guillain-Barré syndrome.
    Van Rhijn I; Bleumink-Pluym NM; Van Putten JP; Van den Berg LH
    J Infect Dis; 2002 Jan; 185(2):262-5. PubMed ID: 11807702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.